TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01994486
Drug: Telaprevir and Sofosbuvir
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
Study: NCT00085410
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03254173
Drug: Mirtazapine 30 mg oral tablets
Normalized name: mirtazapine 30 MG
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
Study: NCT03813030
Drug: Lidocaine 2.5% and Prilocaine 2.5% cream, USP (2.5% lidocaine, 2.5% prilocaine, Actavis Pharma incorporated, USA)
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application in dermal-sampling visit
Study: NCT00426348
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan (80-160mg/day)
Study: NCT00426348
Drug: Probucol
Normalized name: Probucol
DrugBank: Probucol (DB01599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Probucol (750mg/day)
Study: NCT01871792
Drug: Pitavastatin
Normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01617538
Drug: atorvastatin
Normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg per day,duration for 24 weeks
Study: NCT02351102
Drug: Valacyclovir
Normalized name: Valacyclovir
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02620020
Drug: Fasinumab
Normalized name: Fasinumab
DrugBank: Fasinumab (DB12157)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received fasinumab SC or IV, Q4W or Q8W.
Study: NCT00533962
Drug: Anterior Juxtascleral Depot of Anecortave Acetate
Normalized name: OIL OF CAMPHOR
DrugBank: Anecortave acetate (DB05288)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02440750
Drug: Dienogest
Normalized name: Dienogest
DrugBank: Dienogest (DB09123)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 21 days administration of dienogest 2 mg/die
Study: NCT02440750
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 21 days administration of ulipristal acetate 5 mg/die
Study: NCT00452634
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Study: NCT00001757
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01656525
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg subcutaneous doses every 4 weeks for 24 weeks
Study: NCT01656525
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 105 mg subcutaneous doses every 4 weeks for 24 weeks
Study: NCT01656525
Drug: Gantenerumab
Normalized name: Gantenerumab
DrugBank: Gantenerumab (DB12034)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg subcutaneous doses every 4 weeks for 24 weeks
Study: NCT02582671
Drug: Ombitasvir/paritaprevir/ritonavir
Normalized name: ombitasvir/paritaprevir/ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Co-formulated tablet
Study: NCT02582671
Drug: Dasabuvir
Normalized name: Dasabuvir
DrugBank: Dasabuvir (DB09183)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet
Study: NCT02582671
Drug: Ribavirin
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tablet
Study: NCT00430144
Drug: Belotecan(CKD-602)
Normalized name: belotecan
DrugBank: Belotecan (DB12459)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
Study: NCT00452634
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
Study: NCT02086019
Drug: Conservative Arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: crossover to angiogram only if predefined criteria met
Study: NCT00759603
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
Study: NCT00759603
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dose of 375 mg/m\^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
Study: NCT00003176
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003176
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01911364
Drug: Tiotropium
Normalized name: Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Superiority of CHF5993 over Tiotropium
Study: NCT01911364
Drug: BDP/FF + Tiotropium
DrugBank: Tiotropium (DB01409)
Approvals — FDA: no, EMA: no, PMDA: no
Description: non inferiority vs CHF5993
Study: NCT00104130
Drug: KOS-862
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01724892
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01724892
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02278783
Drug: regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
Study: NCT03341884
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single oral dose of 100 mg ipatasertib will be administered.
Study: NCT00424398
Drug: Bepreve
Normalized name: Bepreve
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00424398
Drug: Bepotastine Besilate
Normalized name: Bepotastine besilate
DrugBank: Bepotastine (DB04890)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sterile ophthalmic solution
Study: NCT00095563
Drug: lapatinib ditosylate
Normalized name: Lapatinib Ditosylate
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given orally
Study: NCT03543813
Drug: CX-2029
Normalized name: CX-046684
DrugBank: CX-046684 (DB19414)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CX-2029 Monotherapy
Study: NCT00749203
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose 0.045 mg/kg IV infused over 40 minutes
Study: NCT00749203
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
Study: NCT02150031
Drug: 0.2% Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mouthwash with 10 ml for 1 minute
Study: NCT02150031
Drug: 1% Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: subgingival irrigation
Study: NCT02150031
Drug: 1% Chlorhexidine
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: supragingival irrigation
Study: NCT02150031
Drug: Lidocaine plus adrenaline
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
Study: NCT01400256
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
Study: NCT00943683
Drug: montelukast sodium
Normalized name: Montelukast Sodium
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
Study: NCT00987844
Drug: Prucalopride
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
Study: NCT00302393
Drug: OROS methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
Study: NCT03494257
Drug: Brinzolamide-Brimonidine fixed combination
Normalized name: brimonidine / brinzolamide
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Simbrinza 0.2%-1% Ophthalmic Suspension
Study: NCT00302393
Drug: methylphenidate hydrochloride
Normalized name: Methylphenidate Hydrochloride
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
Study: NCT00426673
Drug: Brivaracetam (ucb34714)
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00382148
Drug: omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SC repeating dose
Study: NCT03404648
Drug: Gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of Gadavist® (Gadobutrol, Bayer) at no more than 0.1 mmol/kg will be administrated intravenously.
Study: NCT00123929
Drug: docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg/m2 every 3 weeks times 4
Study: NCT05707572
Drug: methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: a single injection of 1 mL methylprednisolone \[40 mg\] and 1 mL 2% lignocaine
Study: NCT02792257
Drug: Dronabinol (Marinol®)
Normalized name: Dronabinol
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg - 10mg daily dose
Study: NCT00699283
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg \> 20 mg) for subjects not participating in the follow-up study)
Study: NCT00699283
Drug: Brivaracetam
Normalized name: Brivaracetam
DrugBank: Brivaracetam (DB05541)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg \> 50 mg \> 20 mg) for subjects not participating in the follow-up study)
Study: NCT02714530
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tarceva daily during radiotherapy course
Study: NCT00622193
Drug: anamorelin HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 50 mg tablet
Study: NCT00622193
Drug: anamorelin HCl
Normalized name: Chlorpromazine Hydrochloride
DrugBank: Anamorelin (DB06645)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 100 mg tablet
Study: NCT02117349
Drug: Raplixa
Normalized name: Raplixa
DrugBank: Fibrinogen human (DB09222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raplixa is a biological product approved for use in adults to help control bleeding from small blood vessels when standard surgical techniques, such as suture, ligature or cautery, are ineffective or impractical. When applied to a bleeding site, Raplixa is dissolved in the blood and a reaction starts between the fibrinogen and thrombin proteins. This results in the formation of blood clots to help stop the bleeding.
Study: NCT02704962
Drug: full-dose olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: trifluoperazine 5mg/d
Study: NCT00023322
Drug: Peginterferon Alpha-2a
Normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment
Study: NCT01810809
Drug: 1 ampoule of Hylan GF-20
Normalized name: hylan
DrugBank: 3,4-dimethylaniline (DB03018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
Study: NCT01810809
Drug: 2 ampoules of Hylan GF-20
Normalized name: hylan
DrugBank: 3,4-dimethylaniline (DB03018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
Study: NCT01810809
Drug: 3 ampoules of Hylan GF-20
Normalized name: hylan
DrugBank: 3,4-dimethylaniline (DB03018)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
Study: NCT06252116
Drug: Pregabalin group
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin group
Study: NCT06252116
Drug: Duloxetine group
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Duloxetine group
Study: NCT02768376
Drug: Bupivacaine with Fentanyl (Spinal Anesthesia)
Normalized name: bupivacaine / epinephrine Injection [Sensorcaine with Epinephrine]
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
Study: NCT03009604
Drug: Simethicone
Normalized name: Simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simethicone 40mg oral tablets
Study: NCT03009604
Drug: Enema
Normalized name: Enema
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sodium dihydrogen phosphate dihydrate 19.2 gram \& disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
Study: NCT01446328
Drug: Amisulpride
Normalized name: Amisulpride
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, dose range 50-1200 mg/ day
Study: NCT01446328
Drug: Aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablets, dose range 5-30 mg/ day
Study: NCT01446328
Drug: Olanzapine
Normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, dose range 2.5-20 mg/ day
Study: NCT00820326
Drug: Dolasetron
Normalized name: Dolasetron
DrugBank: Dolasetron (DB00757)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
Study: NCT04790942
Drug: berberine hydrochloride
Normalized name: Berberine Hydrochloride
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: the berberine hydrochloride group (BBR) take berberine hydrochloride tablets (0.4g, 3 times/day, 3 months)
Study: NCT02929524
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
Study: NCT03010540
Drug: MORPHINE PLUS FENTANYL
Normalized name: Fentanyl
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Effect Of Morphine Plus Fentanyl On Emergence Delirium
Study: NCT00185861
Drug: Arsenic Trioxide
Normalized name: Arsenic Trioxide
DrugBank: Arsenic trioxide (DB01169)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02139904
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
Study: NCT00209794
Drug: Sulfadoxine-Pyrimethamine (Fansidar)
Normalized name: pyrimethamine / sulfadoxine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03685448
Drug: Cabozantinib
Normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The 20 mg cabozantinib drug product is a film-coated, white, round, immediate-release tablet. Cabozantinib should not be stored above 25°C (77°F).
Study: NCT04627740
Drug: Retroviral vector-transduced autologous T cells to express anti-ALPP CARs
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide will be administered at dose of 20mg/kg for 1 day and then fludarabine will be given for the next 3 days with 35mg/m2 and then the CAR-T cells will be administered
Study: NCT00496366
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
Study: NCT02718820
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75mg/m2; q21
Study: NCT02718820
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab 200mg, q21
Study: NCT00975091
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Study: NCT00975091
Drug: Entecavir
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
Study: NCT02285829
Drug: Rocuronium Bromide, Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF \>0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
Study: NCT01740336
Drug: GDC-0941
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GDC-0941 will be administered QD orally for 5 consecutive days each week.
Study: NCT01740336
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
Study: NCT00762151
Drug: Prototype (AN0128 Toothpaste)
Normalized name: AN0128
DrugBank: AN0128 (DB05054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AN0128 Toothpaste
Study: NCT00824564
Drug: Tranexamic Acid plus standard of care
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)